134 related articles for article (PubMed ID: 8901613)
1. A tumor-selective somatostatin analog (TT-232) with strong in vitro and in vivo antitumor activity.
Kéri G; Erchegyi J; Horváth A; Mezõ I; Idei M; Vántus T; Balogh A; Vadász Z; Bökönyi G; Seprõdi J; Teplán I; Csuka O; Tejeda M; Gaál D; Szegedi Z; Szende B; Roze C; Kalthoff H; Ullrich A
Proc Natl Acad Sci U S A; 1996 Oct; 93(22):12513-8. PubMed ID: 8901613
[TBL] [Abstract][Full Text] [Related]
2. The antitumor activity of the somatostatin structural derivative (TT-232) on different human tumor xenografts.
Tejeda M; Gaal D; Barna K; Csuka O; Kéri G
Anticancer Res; 2003; 23(5A):4061-6. PubMed ID: 14666719
[TBL] [Abstract][Full Text] [Related]
3. Peptides and antitumor activity. Development and investigation of some peptides with antitumor activity.
Teplán I
Acta Biol Hung; 2000; 51(1):1-29. PubMed ID: 10866357
[TBL] [Abstract][Full Text] [Related]
4. Continuous administration of the somatostatin structural derivative /TT-232/ by subcutaneously implanted osmotic pump improves the efficacy and potency of antitumor therapy in different mouse and human tumor models.
Tejeda M; Gaal D; Hullán L; Csuka O; Schwab R; Szokoloczi O; Kéri GY
Anticancer Res; 2008; 28(5A):2769-74. PubMed ID: 19035308
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of the somatostatin structural derivative (TT-232), against mouse and human melanoma tumor models.
Tejeda M; Gaál D; Hullán L; Schwab R; Szokoloczi O; Kéri G
Anticancer Res; 2007; 27(6B):4015-9. PubMed ID: 18225564
[TBL] [Abstract][Full Text] [Related]
6. TT-232: a somatostatin structural derivative as a potent antitumor drug candidate.
Szende B; Kéri G
Anticancer Drugs; 2003 Sep; 14(8):585-8. PubMed ID: 14501379
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the antitumor efficacy of the somatostatin structural derivative TT-232 on different tumor models.
Tejeda M; Gaál D; Hullán L; Hegymegi-Barakonyi B; Kéri G
Anticancer Res; 2006; 26(5A):3477-83. PubMed ID: 17094470
[TBL] [Abstract][Full Text] [Related]
8. A specifically radiolabeled somatostatin analog with strong antitumor activity induces apoptosis and accumulates in the cytosol and the nucleus of HT29 human colon carcinoma cells.
Szegedi Z; Takács J; Szende B; Vadász Z; Horváth A; Gulyás E; Tóth G; Peták I; Bocsi J; Kéri G
Endocrine; 1999 Feb; 10(1):25-34. PubMed ID: 10403568
[TBL] [Abstract][Full Text] [Related]
9. Antiproliferative efficacy of the somatostatin analogue TT-232 in human melanoma cells and tumours.
Schwab RE; Froidevaux S; Paku S; Tejeda M; Szende B; Pap A; Beglinger C; Eberle AN; Kéri G
Anticancer Res; 2001; 21(1A):71-5. PubMed ID: 11299792
[TBL] [Abstract][Full Text] [Related]
10. In vivo antitumor activity of TT-232 a novel somatostatin analog.
Tejeda M; Gaal D; Schwab RE; Pap A; Keri G
Anticancer Res; 1999; 19(4B):3265-8. PubMed ID: 10652622
[TBL] [Abstract][Full Text] [Related]
11. Antiproliferative activity induced by the somatostatin analogue, TT-232, in human pancreatic cancer cells.
Lee JU; Hosotani R; Wada M; Doi R; Koshiba T; Fujimoto K; Miyamoto Y; Tsuji S; Nakajima S; Hirohashi M; Uehara T; Arano Y; Fujii N; Imamura M
Eur J Cancer; 2002 Jul; 38(11):1526-34. PubMed ID: 12110500
[TBL] [Abstract][Full Text] [Related]
12. Apoptosis is induced in both drug-sensitive and multidrug-resistant hepatoma cells by somatostatin analogue TT-232.
Diaconu CC; Szathmári M; Kéri G; Venetianer A
Br J Cancer; 1999 Jun; 80(8):1197-203. PubMed ID: 10376972
[TBL] [Abstract][Full Text] [Related]
13. Tumor apoptosis induced by epoxide-containing piperazines, a new class of anti-cancer agents.
Eilon GF; Gu J; Slater LM; Hara K; Jacobs JW
Cancer Chemother Pharmacol; 2000; 45(3):183-91. PubMed ID: 10663635
[TBL] [Abstract][Full Text] [Related]
14. Novel antitumor peptide hormones and their effect on signal transduction.
Kéri G; Balogh A; Horváth A; Mezö I; Vadász Z; Bökönyi G; Bajor T; Vántus T; Teplán I; Horváth J
J Steroid Biochem Mol Biol; 1992 Sep; 43(1-3):105-10. PubMed ID: 1356011
[TBL] [Abstract][Full Text] [Related]
15. Lanreotide promotes apoptosis and is not radioprotective in GH3 cells.
Ning S; Knox SJ; Harsh GR; Culler MD; Katznelson L
Endocr Relat Cancer; 2009 Sep; 16(3):1045-55. PubMed ID: 19528243
[TBL] [Abstract][Full Text] [Related]
16. A comparison of the tumor growth inhibitory effect of intermittent and continuous administration of the somatostatin structural derivative TT-232 in various human tumor models.
Tejeda M; Gaál D; Hullán L; Csuka O; Schwab R; Szokoloczi O; Kéri G
Anticancer Res; 2006; 26(4B):3011-5. PubMed ID: 16886628
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, conformational analysis and bioactivity of Lan-7, a lanthionine analog of TT-232.
Li H; Jiang X; Howell SB; Goodman M
J Pept Sci; 2000 Jan; 6(1):26-35. PubMed ID: 10674717
[TBL] [Abstract][Full Text] [Related]
18. Growth inhibitory effect of the somatostatin structural derivative (TT-232) on leukemia models.
Tejeda M; Gaál D; Csuka O; Kéri G
Anticancer Res; 2005; 25(1A):325-30. PubMed ID: 15816555
[TBL] [Abstract][Full Text] [Related]
19. Pro-apoptotic and anti-apoptotic molecules affecting pathways of signal transduction.
Kéri G; Racz G; Magyar K; Orfi L; Horváth A; Schwab R; Hegymegi BB; Szende B
Ann N Y Acad Sci; 2003 Dec; 1010():109-12. PubMed ID: 15033704
[TBL] [Abstract][Full Text] [Related]
20. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.
Ciardiello F; Caputo R; Bianco R; Damiano V; Pomatico G; De Placido S; Bianco AR; Tortora G
Clin Cancer Res; 2000 May; 6(5):2053-63. PubMed ID: 10815932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
